Inflammatory mediators involved in the progression of the metabolic syndrome

Diabetes/Metabolism Research and Reviews

Volumn 28, Issue 5, 2012, Pages 388-394

  Ma, Kuifen ^a   Jin, Xi ^a   Liang, Xingguang ^a   Zhao, Qingwei ^a   Zhang, Xingguo ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Inflammation; Inflammatory mediators; Metabolic syndrome

Indexed keywords

ADIPONECTIN; ANGIOTENSINOGEN; ARACHIDONATE 12 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONIC ACID; C REACTIVE PROTEIN; COLONY STIMULATING FACTOR 1; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 6; LEPTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE SYNTHASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSTACYCLIN; RESISTIN; SUPEROXIDE DISMUTASE; THROMBOXANE; THROMBOXANE A2; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

CYTOKINE PRODUCTION; DISEASE COURSE; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; THROMBOCYTE AGGREGATION;

DIABETES COMPLICATIONS; DIABETES MELLITUS; DISEASE PROGRESSION; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; METABOLIC SYNDROME X;

EID: 84863767472     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2291     Document Type: Review

References (87)

1. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome - a new worldwide definition. Lancet 2005; 366(9491): 1059-1062.
2. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006; 444(7121): 881-887.
3. Cornier MA, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, Stob NR, et al. The metabolic syndrome. Endocr Rev 2008; 29(7): 777-822.
4. Ferrero-Miliani L, Nielsen OH, Andersen PS, Girardin SE. Chronic inflammation: importance of NOD2 and NALP3 in interleukin-1beta generation. Clin Exp Immunol 2007; 147(2): 227-235.
5. Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006; 17(1): 4-12.
6. Strohacker K, McFarlin BK. Influence of obesity, physical inactivity, and weight cycling on chronic inflammation. Front Biosci (Elite Ed) 2010; 2: 98-104.
7. Rajala MW, Scherer PE. Minireview: the adipocyte - at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 2003; 144(9): 3765-3773.
8. Bays HE, Gonzalez-Campoy JM, Bray GA, Kitabchi AE, Bergman DA, Schorr AB, et al. Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert Rev Cardiovasc Ther 2008; 6(3): 343-368.
9. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature 2006; 444(7121): 875-880.
10. Wang Z, Nakayama T. Inflammation, a link between obesity and cardiovascular disease. Mediators Inflamm 2010; 2010: 535918.
11. Bays HE. Adiposopathy is "sick fat" a cardiovascular disease? J Am Coll Cardiol 2011; 57(25): 2461-2473.
12. Lyon CJ, Law RE, Hsueh WA. Minireview: adiposity, inflammation, and atherogenesis. Endocrinology 2003; 144(6): 2195-2200.
13. Vorchheimer DA, Fuster V. Inflammatory markers in coronary artery disease: let prevention douse the flames. JAMA 2001; 286(17): 2154-2156.
14. Mullenix PS, Andersen CA, Starnes BW. Atherosclerosis as inflammation. Ann Vasc Surg 2005; 19(1): 130-138.
15. Brunt EM. Nonalcoholic steatohepatitis. Semin Liver Dis 2004; 24(1): 3-20.
16. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50(8): 1844-1850.
17. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37(4): 917-923.
18. Ferre N, Martinez-Clemente M, Lopez-Parra M, Gonzalez-Periz A, Horrillo R, Planaguma A, et al. Increased susceptibility to exacerbated liver injury in hypercholesterolemic ApoE-deficient mice: potential involvement of oxysterols. Am J Physiol Gastrointest Liver Physiol 2009; 296(3): G553-G562.
19. Elks CM, Francis J. Central adiposity, systemic inflammation, and the metabolic syndrome. Curr Hypertens Rep 2010; 12(2): 99-104.
20. Vykoukal D, Davies MG. Vascular biology of metabolic syndrome. J Vasc Surg 2011; 54(3): 819-831.
21. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444(7121): 860-867.
22. Wubben DP, Adams AK. Metabolic syndrome: what's in a name? WMJ 2006; 105(5): 17-20.
23. Guarente L. Sirtuins as potential targets for metabolic syndrome. Nature 2006; 444(7121): 868-874.
24. Ackermann D, Jones J, Barona J, Calle MC, Kim JE, LaPia B, et al. Waist circumference is positively correlated with markers of inflammation and negatively with adiponectin in women with metabolic syndrome. Nutr Res 2011; 31(3): 197-204.
25. Pfutzner A, Schondorf T, Hanefeld M, Forst T. High-sensitivity C-reactive protein predicts cardiovascular risk in diabetic and nondiabetic patients: effects of insulin-sensitizing treatment with pioglitazone. J Diabetes Sci Technol 2010; 4(3): 706-716.
26. Kang ES, Kim HJ, Kim YM, Lee S, Cha BS, Lim SK, et al. Serum high sensitivity C-reactive protein is associated with carotid intima-media thickness in type 2 diabetes. Diabetes Res Clin Pract 2004; 66SUPPL 1: S115-S120.
27. Anan F, Takahashi N, Nakagawa M, Ooie T, Saikawa T, Yoshimatsu H. High-sensitivity C-reactive protein is associated with insulin resistance and cardiovascular autonomic dysfunction in type 2 diabetic patients. Metabolism 2005; 54(4): 552-558.
28. 1c and insulin resistance in type 2 diabetic men with or without coronary heart disease? J Endocrinol Invest 2005; 28(2): 145-150.
29. Pravenec M, Kajiya T, Zidek V, Landa V, Mlejnek P, Simakova M, et al. Effects of human C-reactive protein on pathogenesis of features of the metabolic syndrome. Hypertension 2011; 57(4): 731-737.
30. Zhou QG, Zhou M, Lou AJ, Xie D, Hou FF. Advanced oxidation protein products induce inflammatory response and insulin resistance in cultured adipocytes via induction of endoplasmic reticulum stress. Cell Physiol Biochem 2010; 26(4-5): 775-786.
31. Giordano P, Del Vecchio GC, Cecinati V, Delvecchio M, Altomare M, De Palma F, et al. Metabolic, inflammatory, endothelial and haemostatic markers in a group of Italian obese children and adolescents. Eur J Pediatr 2011; 170(7): 845-850.
32. Espinola-Klein C, Gori T, Blankenberg S, Munzel T. Inflammatory markers and cardiovascular risk in the metabolic syndrome. Front Biosci 2011; 16: 1663-1674.
33. Pietilainen KH, Kannisto K, Korsheninnikova E, Rissanen A, Kaprio J, Ehrenborg E, et al. Acquired obesity increases CD68 and tumor necrosis factor-alpha and decreases adiponectin gene expression in adipose tissue: a study in monozygotic twins. J Clin Endocrinol Metab 2006; 91(7): 2776-2781.
34. Matsumaru K, Ji C, Kaplowitz N. Mechanisms for sensitization to TNF-induced apoptosis by acute glutathione depletion in murine hepatocytes. Hepatology 2003; 37(6): 1425-1434.
35. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006; 86(2): 515-581.
36. Hajri T, Tao H, Wattacheril J, Marks-Shulman P, Abumrad NN. Regulation of adiponectin production by insulin: interactions with tumor necrosis factor-alpha and interleukin-6. Am J Physiol Endocrinol Metab 2011; 300(2): E350-E360.
37. Gupta A, Gupta V, Singh AK, Tiwari S, Agrawal S, Natu SM, et al. Interleukin-6 G-174C gene polymorphism and serum resistin levels in North Indian women: potential risk of metabolic syndrome. Hum Exp Toxicol 2010; 30(10): 1445-1453.
38. Allende-Vigo MZ. Pathophysiologic mechanisms linking adipose tissue and cardiometabolic risk. Endocr Pract 2010; 16(4): 692-698.
39. Bluher M. Adipose tissue dysfunction in obesity. Exp Clin Endocrinol Diabetes 2009; 117(6): 241-250.
40. Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab 2000; 11(8): 327-332.
41. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011; 11(2): 85-97.
42. O'Rourke L, Gronning LM, Yeaman SJ, Shepherd PR. Glucose-dependent regulation of cholesterol ester metabolism in macrophages by insulin and leptin. J Biol Chem 2002; 277(45): 42557-42562.
43. Esteghamati A, Noshad S, Khalilzadeh O, Morteza A, Nazeri A, Meysamie A, et al. Contribution of serum leptin to metabolic syndrome in obese and nonobese subjects. Arch Med Res 2011; 42(3): 244-251.
44. Rahmouni K. Leptin-induced sympathetic nerve activation: signaling mechanisms and cardiovascular consequences in obesity. Curr Hypertens Rev 2010; 6(2): 104-209.
45. Tham DM, Martin-McNulty B, Wang YX, Wilson DW, Vergona R, Sullivan ME, et al. Angiotensin II is associated with activation of NF-kappaB-mediated genes and downregulation of PPARs. Physiol Genomics 2002; 11(1): 21-30.
46. Gopal K, Kumar K, Nandini R, Jahan P, Kumar MJ. High fat diet containing cholesterol induce aortic aneurysm through recruitment and proliferation of circulating agranulocytes in apoE knock out mice model. J Thromb Thrombolysis 2010; 30(2): 154-163.
47. Cai H, Li Z, Dikalov S, Holland SM, Hwang J, Jo H, et al. NAD(P)H oxidase-derived hydrogen peroxide mediates endothelial nitric oxide production in response to angiotensin II. J Biol Chem 2002; 277(50): 48311-48317.
48. Mertens I, Verrijken A, Michiels JJ, Van der Planken M, Ruige JB, Van Gaal LF. Among inflammation and coagulation markers, PAI-1 is a true component of the metabolic syndrome. Int J Obes (Lond) 2006; 30(8): 1308-1314.
49. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 2004; 24(1): 29-33.
50. Matsuzawa Y. Adiponectin: a key player in obesity related disorders. Curr Pharm Des 2010; 16(17): 1896-1901.
51. Pyrzak B, Ruminska M, Popko K, Demkow U. Adiponectin as a biomarker of the metabolic syndrome in children and adolescents. Eur J Med Res 2010; 15(SUPPL 2): 147-151.
52. Bahia L, Aguiar LG, Villela N, Bottino D, Godoy-Matos AF, Geloneze B, et al. Relationship between adipokines, inflammation, and vascular reactivity in lean controls and obese subjects with metabolic syndrome. Clinics (Sao Paulo) 2006; 61(5): 433-440.
53. Rolland C, Hession M, Broom I. Effect of weight loss on adipokine levels in obese patients. Diabetes Metab Syndr Obes 2011; 4: 315-323.
54. I Frisbee JC, Hollander JM, Brock RW, Yu HG, Boegehold MA. ntegration of skeletal muscle resistance arteriolar reactivity for perfusion responses in the metabolic syndrome. Am J Physiol Regul Integr Comp Physiol 2009; 296(6): R1771-R1782.
55. Sanchez A, Contreras C, Villalba N, Martinez P, Martinez AC, Briones A, et al. Altered arachidonic acid metabolism via COX-1 and COX-2 contributes to the endothelial dysfunction of penile arteries from obese Zucker rats. Br J Pharmacol 2010; 159(3): 604-616.
56. Linton MF, Fazio S. Macrophages, inflammation, and atherosclerosis. Int J Obes Relat Metab Disord 2003; 27(SUPPL 3): S35-S40.
57. Szerafin T, Erdei N, Fulop T, Pasztor ET, Edes I, Koller A, et al. Increased cyclooxygenase-2 expression and prostaglandin-mediated dilation in coronary arterioles of patients with diabetes mellitus. Circ Res 2006; 99(5): e12-e17.
58. Liu TT, Shih KC, Kao CC, Cheng WT, Hsieh PS. Importance of cyclooxygenase 2-mediated low-grade inflammation in the development of fructose-induced insulin resistance in rats. Chin J Physiol 2009; 52(2): 65-71.
59. Bagi Z. Mechanisms of coronary microvascular adaptation to obesity. Am J Physiol Regul Integr Comp Physiol 2009; 297(3): R556-R567.
60. Vessieres E, B de Chantemele EJ, Toutain B, Guihot AL, Jardel A, Loufrani L, et al. Cyclooxygenase-2 inhibition restored endothelium-mediated relaxation in old obese zucker rat mesenteric arteries. Front Physiol 2010; 1: 145.
61. Quilley J, Chen YJ. Role of COX-2 in the enhanced vasoconstrictor effect of arachidonic acid in the diabetic rat kidney. Hypertension 2003; 42(4): 837-843.
62. Gao XR, Adhikari CM, Peng LY, Guo XG, Zhai YS, He XY, et al. Efficacy of different doses of aspirin in decreasing blood levels of inflammatory markers in patients with cardiovascular metabolic syndrome. J Pharm Pharmacol 2009; 61(11): 1505-1510.
63. Hsieh PS, Tsai HC, Kuo CH, Chan JY, Shyu JF, Cheng WT, et al. Selective COX2 inhibition improves whole body and muscular insulin resistance in fructose-fed rats. Eur J Clin Invest 2008; 38(11): 812-819.
64. Yokozawa T, Kim HJ, Cho EJ. Gravinol ameliorates high-fructose-induced metabolic syndrome through regulation of lipid metabolism and proinflammatory state in rats. J Agric Food Chem 2008; 56(13): 5026-5032.
65. Horrillo R, Gonzalez-Periz A, Martinez-Clemente M, Lopez-Parra M, Ferre N, Titos E, et al. 5-Lipoxygenase activating protein signals adipose tissue inflammation and lipid dysfunction in experimental obesity. J Immunol 2010; 184(7): 3978-3987.
66. Chakrabarti SK, Wen Y, Dobrian AD, Cole BK, Ma Q, Pei H, et al. Evidence for activation of inflammatory lipoxygenase pathways in visceral adipose tissue of obese Zucker rats. Am J Physiol Endocrinol Metab 2011; 300(1): E175-E187.
67. Martinez-Clemente M, Ferre N, Gonzalez-Periz A, Lopez-Parra M, Horrillo R, Titos E, et al. 5-Lipoxygenase deficiency reduces hepatic inflammation and tumor necrosis factor alpha-induced hepatocyte damage in hyperlipidemia-prone ApoE-null mice. Hepatology 2010; 51(3): 817-827.
68. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001; 294(5548): 1871-1875.
69. Lopez-Parra M, Titos E, Horrillo R, Ferre N, Gonzalez-Periz A, Martinez-Clemente M, et al. Regulatory effects of arachidonate 5-lipoxygenase on hepatic microsomal TG transfer protein activity and VLDL-triglyceride and apoB secretion in obese mice. J Lipid Res 2008; 49(12): 2513-2523.
70. Zhao L, Moos MP, Grabner R, Pedrono F, Fan J, Kaiser B, et al. The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nat Med 2004; 10(9): 966-973.
71. Horrillo R, Planaguma A, Gonzalez-Periz A, Ferre N, Titos E, Miquel R, et al. Comparative protection against liver inflammation and fibrosis by a selective cyclooxygenase-2 inhibitor and a nonredox-type 5-lipoxygenase inhibitor. J Pharmacol Exp Ther 2007; 323(3): 778-786.
72. Back M. Leukotrienes: potential therapeutic targets in cardiovascular diseases. Bull Acad Natl Med 2006; 190(7): 1511-1518; discussion 18-21.
73. Qiu H, Gabrielsen A, Agardh HE, Wan M, Wetterholm A, Wong CH, et al. Expression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability. Proc Natl Acad Sci U S A 2006; 103(21): 8161-8166.
74. Back M, Bu DX, Branstrom R, Sheikine Y, Yan ZQ, Hansson GK. Leukotriene B4 signaling through NF-kappaB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia. Proc Natl Acad Sci U S A 2005; 102(48): 17501-17506.
75. Hlawaty H, Jacob MP, Louedec L, Letourneur D, Brink C, Michel JB, et al. Leukotriene receptor antagonism and the prevention of extracellular matrix degradation during atherosclerosis and in-stent stenosis. Arterioscler Thromb Vasc Biol 2009; 29(4): 518-524.
76. Chen M, Yang ZD, Smith KM, Carter JD, Nadler JL. Activation of 12-lipoxygenase in proinflammatory cytokine-mediated beta cell toxicity. Diabetologia 2005; 48(3): 486-495.
77. Puri P, Wiest MM, Cheung O, Mirshahi F, Sargeant C, Min HK, et al. The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology 2009; 50(6): 1827-1838.
78. Martinez-Clemente M, Ferre N, Titos E, Horrillo R, Gonzalez-Periz A, Moran-Salvador E, et al. Disruption of the 12/15-lipoxygenase gene (Alox15) protects hyperlipidemic mice from nonalcoholic fatty liver disease. Hepatology 2010; 52(6): 1980-1991.
79. Wen Y, Gu J, Vandenhoff GE, Liu X, Nadler JL. Role of 12/15-lipoxygenase in the expression of MCP-1 in mouse macrophages. Am J Physiol Heart Circ Physiol 2008; 294(4): H1933-H1938.
80. Cyrus T, Witztum JL, Rader DJ, Tangirala R, Fazio S, Linton MF, et al. Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in Apo E-deficient mice. J Clin Invest 1999; 103(11): 1597-1604.
81. Cyrus T, Pratico D, Zhao L, Witztum JL, Rader DJ, Rokach J, et al. Absence of 12/15-lipoxygenase expression decreases lipid peroxidation and atherogenesis in apolipoprotein E-deficient mice. Circulation 2001; 103(18): 2277-2282.
82. Bleich D, Chen S, Zipser B, Sun D, Funk CD, Nadler JL. Resistance to type 1 diabetes induction in 12-lipoxygenase knockout mice. J Clin Invest 1999; 103(10): 1431-1436.
83. McDuffie M, Maybee NA, Keller SR, Stevens BK, Garmey JC, Morris MA, et al. Nonobese diabetic (NOD) mice congenic for a targeted deletion of 12/15-lipoxygenase are protected from autoimmune diabetes. Diabetes 2008; 57(1): 199-208.
84. Nunemaker CS, Chen M, Pei H, Kimble SD, Keller SR, Carter JD, et al. 12-Lipoxygenase-knockout mice are resistant to inflammatory effects of obesity induced by Western diet. Am J Physiol Endocrinol Metab 2008; 295(5): E1065-E1075.
85. Sears DD, Miles PD, Chapman J, Ofrecio JM, Almazan F, Thapar D, et al. 12/15-Lipoxygenase is required for the early onset of high fat diet-induced adipose tissue inflammation and insulin resistance in mice. PLoS One 2009; 4(9): e7250.
86. Kayama Y, Minamino T, Toko H, Sakamoto M, Shimizu I, Takahashi H, et al. Cardiac 12/15 lipoxygenase-induced inflammation is involved in heart failure. J Exp Med 2009; 206(7): 1565-1574.
87. Chakrabarti SK, Cole BK, Wen Y, Keller SR, Nadler JL. 12/15-Lipoxygenase products induce inflammation and impair insulin signaling in 3T3-L1 adipocytes. Obesity (Silver Spring) 2009; 17(9): 1657-1663.